Company intelligence / Profile preview
Pharma Power Biotec Co., Ltd.
- Ownership
- Private
- Employees
- ~40
- Development stage
- Commercial
Overview
The company’s lead asset is Radion™ PDT for the treatment of oral precancerous lesions. A Phase II clinical trial has been completed evaluating efficacy and safety in patients with oral verrucous hyperplasia or erythroleukoplakia. No published pivotal results yet; highest phase reached is Phase II.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Photodynamic therapy (PDT)Mucoadhesive thermo-responsive medicament-carrier compositionsHealth foods for metabolic health/diabetes/weight loss
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Pharma Power Biotec Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharma Power Biotec Co., Ltd..